You could be right of course, though I wouldn't think a general top-line PR would be an issue prior to their presenting at a major conference. Do we know how MRK has reacted in similar situations before with respect to other drugs partnered with other biotechs?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.